The research of Dr. Sévigny’s team focusses on the functions of extracellular nucleotides, exerted through the activation of P2 receptors, with an emphasis on the enzymes that regulate their concentrations at the cell surface.  Dr. Sévigny and his team have also identified, cloned and characterized six new genes, including the first member of a new family encoding enzymes called NTPDases.  His team is interested in several biological functions including the regulation of inflammation in response to pathogenic determinants, the migration of immune cells, the functions of leukocytes, the contraction of smooth muscles, and in particular the regulation of inflammation of the intestine with an emphasis on epithelial cells and on a potential treatment for inflammatory bowel disease.

Dr Sévigny’s team uses animal models with KO mice as well as methods of cell biology (murine and human primary cells), pharmacology, biochemistry and immunology.

CHUL
2705, boulevard Laurier
T1-49
Québec, Québec
Canada G1V 4G2
303 entries « 2 of 31 »

Bi C, Schäkel L, Mirza S, Sylvester K, Pelletier J, Lee SY, Pillaiyar T, Sévigny J, Müller CE

Synthesis and structure-activity relationships of ticlopidine derivatives and analogs as inhibitors of ectonucleotidase CD39

Journal Article

Bioorg Chem, 135 , 2023.

Abstract | Links:

Noronha-Matos JB, Pinto-Cardoso R, Bessa-Andrês C, Magalhães-Cardoso MT, Ferreirinha F, Costa MA, Marinhas J, Freitas R, Lemos R, Vilaça A, Oliveira A, Pelletier J, Sévigny J, Correia-de-Sá P

Silencing NTPDase3 activity rehabilitates the osteogenic commitment of post-menopausal stem cell bone progenitors

Journal Article

Stem Cell Res Ther, 14 (1), 2023.

Abstract | Links:

Huang X, Gu W, Zhang J, Lan Y, Colarusso JL, Li S, Pertl C, Lu J, Kim H, Zhu J, Breault DT, Sévigny J, Zhou Q

Stomach-derived human insulin-secreting organoids restore glucose homeostasis

Journal Article

Nat Cell Biol, 25 (5), 2023.

Abstract | Links:

Rubenich DS, de Souza PO, Omizzollo N, Aubin MR, Basso PJ, Silva LM, da Silva EM, Teixeira FC, Gentil GFS, Domagalski JL, Cunha MT, Gadelha KA, Diel LF, Gelsleichter NE, Rubenich AS, Lenz GS, de Abreu AM, Kroeff GM, Paz AH, Visioli F, Lamers ML, Wink MR, Worm PV, Araújo AB, Sévigny J, Câmara NOS, Ludwig N, Braganhol E

Tumor-neutrophil crosstalk promotes in vitro and in vivo glioblastoma progression

Journal Article

Front Immunol, 14 , 2023.

Abstract | Links:

Jalil S, Ullah S, Zaraei SO, Sbenati RM, Shahin AI, AlKubaisi BO, Pelletier J, Sévigny J, Al-Tel TH, Iqbal J, El-Gamal MI

Synthesis and biological evaluation of sulfamate derivatives as inhibitors of carbonic anhydrases II and IX

Journal Article

Med Chem Res, 32 (5), 2023.

Abstract | Links:

da Silva ÁC, Scholl JN, de Fraga Dias A, Weber AF, Morrone FB, Cruz-López O, Conejo-García A, Campos JM, Sévigny J, Figueiró F, Battastini AMO

Preclinical evaluation of bozepinib in bladder cancer cell lines: modulation of the NPP1 enzyme

Journal Article

Purinergic Signal, 2023.

Abstract | Links:

Favre J, Roy C, Guihot AL, Drouin A, Laprise M, Gillis MA, Robson SC, Thorin E, Sévigny J, Henrion D, Kauffenstein G

NTPDase1/CD39 Ectonucleotidase Is Necessary for Normal Arterial Diameter Adaptation to Flow

Journal Article

Int J Mol Sci, 24 (20), 2023.

Abstract | Links:

Khan Jadoon MS, Pelletier J, Sévigny J, Iqbal J

Synthesis of new class of indole acetic acid sulfonate derivatives as ectonucleotidases inhibitors

Journal Article

RSC Adv, 13 (42), 2023.

Abstract | Links:

Lopez V, Schuh HJM, Mirza S, Vaaßen VJ, Schmidt MS, Sylvester K, Idris RM, Renn C, Schäkel L, Pelletier J, Sévigny J, Naggi A, Scheffler B, Lee SY, Bendas G, Müller CE

Heparins are potent inhibitors of ectonucleotide pyrophosphatase/phospho-diesterase-1 (NPP1) - a promising target for the immunotherapy of cancer

Journal Article

Front Immunol, 14 , 2023.

Abstract | Links:

Zaman G, Ullah S, Uzair M, Batool S, Ahmad H, Ullah F, Pelletier J, Sévigny J, Iqbal J, Hassan A

Synthesis of Thieno[3,2-d]pyrimidine Derivatives through Sequential SN Ar and Suzuki Reactions as Selective h-NTPDase Inhibitors

Journal Article

ChemMedChem, 18 (14), 2023.

Abstract | Links:

303 entries « 2 of 31 »
Signaler des ajouts ou des modifications

Active projects

  • A recombinant soluble NTPDase8 as a novel biological treatment for inflammatory bowel disease, from 2021-10-01 to 2026-09-30
  • Ectonucleotidases and Extracellular Nucleotides in Smooth Muscle Cell Contraction, from 2023-04-01 to 2028-03-31
  • Novel P2Y6 antagonists as a potential therapy for inflammatory bowel disease, from 2021-07-01 to 2025-06-30
  • Regroupement Québécois de Recherche sur la Fonction, l’Ingénierie et les Applications des Protéines, from 2024-04-01 to 2030-03-31

Recently finished projects

  • A novel approach to treating inflammatory bowel diseases through the blocking of P2Y6 receptors, from 2018-04-01 to 2023-03-31
  • Scaling up the production of recombinant human NTPDase8 in CHO expression system for in vivo testing, from 2023-09-01 to 2024-03-31
Data provided by the Université Laval research projects registery